A randomized phase II trial of adjuvant trastuzumab emtansine (T-DM1) followed by subcutaneous trastuzumab versus paclitaxel in combination with subcutaneous trastuzumab for Stage I HER2-positive breast cancer (ATEMPT 2.0)
ENROLLING
Trial ID:
NCT04893109 Protocol # :
21-159
Phase
II
Disease Sites
Breast
Principal Investigator
Tolaney, Sara, M
Site Investigator
Briccetti, Frederick
Giordano, Sara
Harris, Katherine
Hu, Jingjing
Rosenstock, Aron, S.
Sanz- Altamira, Pedro
Site Research Nurses
Brule, Maurice, N.
Caradonna, Lisa
Casella, Allison
Cronis, Charles, Lewis
Cung, Connie
Gentile, Alissa
Ginter, Lindsey
Houghton, Nicole
Jeon, Maryangel, H.
Kasparian, Elizabeth
Kosinski, Michelle
Kuhlman, Rachel
Loeser, Wendy
Macauley, Colleen
Miles, Brandy
Patel, Nikita
Piper, Audrey, L.
Quinn, Caroline
Roche, Kathleen, A.
Rutter, Morgan
Trial Description
Call 877-DF-TRIAL (877-338-7425) to learn more about this clinical trial, protocol #21-159
21-159